Related Experiment Video

Updated: Aug 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Influence of recent trials on essential arterial hypertension management]

Patrick Rossignol1, Sylvie Le Coz, Pierre-François Plouin

  • 1Unité d'hypertension artérielle, Hôpital européen Georges Pompidou, 75908 Paris Cedex 15. patrick.rossignol@hop.egp.ap-hop-paris.fr

La Revue Du Praticien
|June 30, 2004
PubMed

Insights

Updated hypertension guidelines emphasize achieving blood pressure targets below 140/90 mmHg, with diuretics often needed. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARAII) show promise in preventing heart and kidney failure.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Context:

  • Recent updates to U.S. (JNC7), European (ESH/ESC), and World Health Organization (WHO) guidelines for managing arterial essential hypertension.
  • Hypertension management aims to prevent cardiovascular complications like stroke and myocardial infarction.

Purpose:

  • To summarize updated hypertension management guidelines and therapeutic targets.
  • To compare the efficacy of different antihypertensive drug classes.

Summary:

  • Therapeutic blood pressure target is <140/90 mmHg, or <130/80 mmHg for diabetics.
  • Diuretic combination therapy is frequently required to achieve target blood pressure.
  • While minor differences in cardiovascular outcomes exist between older and newer antihypertensives, ACE inhibitors (ACEI) and ARAII demonstrate particular efficacy in preventing cardiac and renal complications.

Impact:

  • Provides clinicians with evidence-based recommendations for optimizing hypertension treatment.
  • Highlights the role of specific drug classes in mitigating long-term cardiovascular and renal damage.
  • Informs patient management strategies to reduce the burden of hypertension-related morbidity.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...